<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00504</drugbank-id>
  <drugbank-id>APRD00733</drugbank-id>
  <name>Levallorphan</name>
  <description>An opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties. It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants. (From Martindale, The Extra Pharmacopoeia, 30th ed, p683)</description>
  <cas-number>152-02-3</cas-number>
  <unii>353613BU4U</unii>
  <average-mass>283.4079</average-mass>
  <monoisotopic-mass>283.193614427</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids.</indication>
  <pharmacodynamics>Levallorphan, an opioid antagonist similar to naloxone, is used to treat drug overdoses. Levallorphan differs from naloxone in that it also possesses some agonist properties. It is an analogue of levelorphanol that counteracts the actions of narcotic analgesics such as morphine. It is used especially in the treatment of respiratory depression due to narcotic overdoses. Levallorphan prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. Also, it can reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.</pharmacodynamics>
  <mechanism-of-action>Levallorphan antagonizes opioid effects by competing for the same receptor sites. It binds to the opioid mu receptor and the nicotinic acetylcholine receptor alpha2/alpha3.</mechanism-of-action>
  <toxicity>Oral, rat LD&lt;sub&gt;50&lt;/sub&gt;: 109&amp;plusmn;4 mg/kg</toxicity>
  <metabolism>Hepatic.</metabolism>
  <absorption>Rapidly absorbed.</absorption>
  <half-life>1 hour</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.</description>
    <direct-parent>Morphinans</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Alkaloids and derivatives</superclass>
    <class>Morphinans</class>
    <subclass/>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>Aralkylamines</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzazocines</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenanthrenes and derivatives</alternative-parent>
    <alternative-parent>Piperidines</alternative-parent>
    <alternative-parent>Tetralins</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>Amine</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzazocine</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Morphinan</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenanthrene</substituent>
    <substituent>Piperidine</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
    <substituent>Tetralin</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001040</drugbank-id>
      <name>Levallorphan tartrate</name>
      <unii>U0VSF7HTN0</unii>
      <cas-number>71-82-9</cas-number>
      <inchikey>FWMLYVACGDQRFU-ZTMWJVNESA-N</inchikey>
      <average-mass>433.501</average-mass>
      <monoisotopic-mass>433.210052342</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="italian" coder="dcit">Levallofano</synonym>
    <synonym language="german" coder="inn/ban">Levallorphan</synonym>
    <synonym language="french" coder="inn">LÃ©vallorphane</synonym>
    <synonym language="latin" coder="inn">Levallorphanum</synonym>
    <synonym language="spanish" coder="inn">Levalorfano</synonym>
  </synonyms>
  <products/>
  <international-brands>
    <international-brand>
      <name>Lorfan</name>
      <company>Takeda</company>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers>
    <manufacturer generic="false" url="">Hoffmann la roche inc</manufacturer>
  </manufacturers>
  <prices/>
  <categories>
    <category>
      <category>Alkaloids</category>
      <mesh-id>D000470</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Morphinans</category>
      <mesh-id>D009019</mesh-id>
    </category>
    <category>
      <category>Opiate Alkaloids</category>
      <mesh-id>D053610</mesh-id>
    </category>
    <category>
      <category>Opioid Antagonists</category>
      <mesh-id>D009292</mesh-id>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Phenanthrenes</category>
      <mesh-id>D010616</mesh-id>
    </category>
    <category>
      <category>Sensory System Agents</category>
      <mesh-id>D018689</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06800</drugbank-id>
      <name>Methylnaltrexone</name>
      <description>Levallorphan may increase the opioid antagonism activities of Methylnaltrexone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09049</drugbank-id>
      <name>Naloxegol</name>
      <description>Levallorphan may increase the opioid antagonism activities of Naloxegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The therapeutic efficacy of Tramadol can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The therapeutic efficacy of Morphine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The therapeutic efficacy of Codeine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The therapeutic efficacy of Methadone can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The therapeutic efficacy of Meperidine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The therapeutic efficacy of Oxycodone can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>The therapeutic efficacy of Butorphanol can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The therapeutic efficacy of Pentazocine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The therapeutic efficacy of Naltrexone can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The therapeutic efficacy of Sufentanil can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The therapeutic efficacy of Alfentanil can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The therapeutic efficacy of Fentanyl can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>The therapeutic efficacy of Nalbuphine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>The therapeutic efficacy of Levorphanol can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The therapeutic efficacy of Remifentanil can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The therapeutic efficacy of Buprenorphine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>The therapeutic efficacy of Hydrocodone can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>The therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The therapeutic efficacy of Oxymorphone can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>The therapeutic efficacy of Dezocine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl acetate</name>
      <description>The therapeutic efficacy of Methadyl acetate can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>The therapeutic efficacy of Dihydroetorphine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Diamorphine</name>
      <description>The therapeutic efficacy of Diamorphine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01459</drugbank-id>
      <name>Bezitramide</name>
      <description>The therapeutic efficacy of Bezitramide can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The therapeutic efficacy of Ethylmorphine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>The therapeutic efficacy of Etorphine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>The therapeutic efficacy of Dextromoramide can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01531</drugbank-id>
      <name>Desomorphine</name>
      <description>The therapeutic efficacy of Desomorphine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>The therapeutic efficacy of Carfentanil can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The therapeutic efficacy of Dihydrocodeine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>The therapeutic efficacy of Alphacetylmethadol can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>The therapeutic efficacy of Dihydromorphine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>The therapeutic efficacy of Tapentadol can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The therapeutic efficacy of Ketobemidone can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>The therapeutic efficacy of DPDPE can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>The therapeutic efficacy of Lofentanil can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09272</drugbank-id>
      <name>Eluxadoline</name>
      <description>The therapeutic efficacy of Eluxadoline can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The therapeutic efficacy of Opium can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>The therapeutic efficacy of Normethadone can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>The therapeutic efficacy of Piritramide can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13160</drugbank-id>
      <name>Alphaprodine</name>
      <description>The therapeutic efficacy of Alphaprodine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13454</drugbank-id>
      <name>Nicomorphine</name>
      <description>The therapeutic efficacy of Nicomorphine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13478</drugbank-id>
      <name>Meptazinol</name>
      <description>The therapeutic efficacy of Meptazinol can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>The therapeutic efficacy of Phenoperidine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13606</drugbank-id>
      <name>Phenazocine</name>
      <description>The therapeutic efficacy of Phenazocine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13787</drugbank-id>
      <name>Tilidine</name>
      <description>The therapeutic efficacy of Tilidine can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15360</drugbank-id>
      <name>Carfentanil, C-11</name>
      <description>The therapeutic efficacy of Carfentanil, C-11 can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15465</drugbank-id>
      <name>Benzhydrocodone</name>
      <description>The therapeutic efficacy of Benzhydrocodone can be decreased when used in combination with Levallorphan.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.91</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.52e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.76</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(1R,9R,10R)-17-(prop-2-en-1-yl)-17-azatetracyclo[7.5.3.0Â¹,Â¹â°.0Â²,â·]heptadeca-2(7),3,5-trien-4-ol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>levallorphan</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>283.4079</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>283.193614427</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@@]12CCCC[C@@]11CCN(CC=C)[C@@H]2CC2=C1C=C(O)C=C2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C19H25NO</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C19H25NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h2,6-7,13,16,18,21H,1,3-5,8-12H2/t16-,18+,19+/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>OZYUPQUCAUTOBP-QXAKKESOSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>23.47</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>87.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>32.68</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>10.36</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>9.41</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>633 mg/L</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>181 Â°C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.48</value>
      <source>HANSCH,C ET AL. (1995)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>6431</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5359371</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505682</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07069</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>10481920</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50326673</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164749284</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000348</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Levallorphan</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1254682</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000683</smpdb-id>
      <name>Levallorphan Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00171</drugbank-id>
          <name>ATP</name>
        </drug>
        <drug>
          <drugbank-id>DB00368</drugbank-id>
          <name>Norepinephrine</name>
        </drug>
        <drug>
          <drugbank-id>DB00504</drugbank-id>
          <name>Levallorphan</name>
        </drug>
        <drug>
          <drugbank-id>DB00988</drugbank-id>
          <name>Dopamine</name>
        </drug>
        <drug>
          <drugbank-id>DB01345</drugbank-id>
          <name>Potassium cation</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>P35372</uniprot-id>
        <uniprot-id>P17787</uniprot-id>
        <uniprot-id>P43681</uniprot-id>
        <uniprot-id>O00555</uniprot-id>
        <uniprot-id>Q02641</uniprot-id>
        <uniprot-id>Q9NY47</uniprot-id>
        <uniprot-id>Q9Y5Y9</uniprot-id>
        <uniprot-id>Q07699</uniprot-id>
        <uniprot-id>Q9NZV8</uniprot-id>
        <uniprot-id>Q9NS61</uniprot-id>
        <uniprot-id>P05023</uniprot-id>
        <uniprot-id>P50993</uniprot-id>
        <uniprot-id>P13637</uniprot-id>
        <uniprot-id>Q13733</uniprot-id>
        <uniprot-id>P05026</uniprot-id>
        <uniprot-id>P14415</uniprot-id>
        <uniprot-id>P54709</uniprot-id>
        <uniprot-id>B7ZKV8</uniprot-id>
        <uniprot-id>P54710</uniprot-id>
        <uniprot-id>P01189</uniprot-id>
        <uniprot-id>P01203</uniprot-id>
        <uniprot-id>P16519</uniprot-id>
        <uniprot-id>Q05586</uniprot-id>
        <uniprot-id>Q12879</uniprot-id>
        <uniprot-id>Q8TCU5</uniprot-id>
        <uniprot-id>P35348</uniprot-id>
        <uniprot-id>P08908</uniprot-id>
        <uniprot-id>P23975</uniprot-id>
        <uniprot-id>P31645</uniprot-id>
        <uniprot-id>Q01959</uniprot-id>
        <uniprot-id>P21728</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000770</id>
      <name>Mu-type opioid receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>partial agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5032</ref-id>
            <pubmed-id>8968334</pubmed-id>
            <citation>Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41.</citation>
          </article>
          <article>
            <ref-id>A5033</ref-id>
            <pubmed-id>7723747</pubmed-id>
            <citation>Traynor JR, Nahorski SR: Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 1995 Apr;47(4):848-54.</citation>
          </article>
          <article>
            <ref-id>A5034</ref-id>
            <pubmed-id>9016350</pubmed-id>
            <citation>Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR: mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol. 1997 Jan;51(1):87-96.</citation>
          </article>
          <article>
            <ref-id>A5035</ref-id>
            <pubmed-id>8819494</pubmed-id>
            <citation>Emmerson PJ, Clark MJ, Mansour A, Akil H, Woods JH, Medzihradsky F: Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther. 1996 Sep;278(3):1121-7.</citation>
          </article>
          <article>
            <ref-id>A5036</ref-id>
            <pubmed-id>9862398</pubmed-id>
            <citation>Morgan D, Picker MJ: The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor. Psychopharmacology (Berl). 1998 Nov;140(1):20-8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P35372" source="Swiss-Prot">
        <name>Mu-type opioid receptor</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.</specific-function>
        <gene-name>OPRM1</gene-name>
        <locus>6q24-q25</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>69-93
107-131
143-165
186-207
231-255
284-307
315-338</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.29</theoretical-pi>
        <molecular-weight>44778.855</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8156</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>OPRM1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L25119</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>452073</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35372</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>OPRM_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hMOP</synonym>
          <synonym>M-OR-1</synonym>
          <synonym>MOP</synonym>
          <synonym>MOR1</synonym>
          <synonym>Mu opiate receptor</synonym>
          <synonym>Mu opioid receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001536|Mu-type opioid receptor
MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI
FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI
YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI
EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021649|Mu-type opioid receptor (OPRM1)
ATGGACAGCAGCGCTGCCCCCACGAACGCCAGCAATTGCACTGATGCCTTGGCGTACTCA
AGTTGCTCCCCAGCACCCAGCCCCGGTTCCTGGGTCAACTTGTCCCACTTAGATGGCAAC
CTGTCCGACCCATGCGGTCCGAACCGCACCGACCTGGGCGGGAGAGACAGCCTGTGCCCT
CCGACCGGCAGTCCCTCCATGATCACGGCCATCACGATCATGGCCCTCTACTCCATCGTG
TGCGTGGTGGGGCTCTTCGGAAACTTCCTGGTCATGTATGTGATTGTCAGATACACCAAG
ATGAAGACTGCCACCAACATCTACATTTTCAACCTTGCTCTGGCAGATGCCTTAGCCACC
AGTACCCTGCCCTTCCAGAGTGTGAATTACCTAATGGGAACATGGCCATTTGGAACCATC
CTTTGCAAGATAGTGATCTCCATAGATTACTATAACATGTTCACCAGCATATTCACCCTC
TGCACCATGAGTGTTGATCGATACATTGCAGTCTGCCACCCTGTCAAGGCCTTAGATTTC
CGTACTCCCCGAAATGCCAAAATTATCAATGTCTGCAACTGGATCCTCTCTTCAGCCATT
GGTCTTCCTGTAATGTTCATGGCTACAACAAAATACAGGCAAGGTTCCATAGATTGTACA
CTAACATTCTCTCATCCAACCTGGTACTGGGAAAACCTGCTGAAGATCTGTGTTTTCATC
TTCGCCTTCATTATGCCAGTGCTCATCATTACCGTGTGCTATGGACTGATGATCTTGCGC
CTCAAGAGTGTCCGCATGCTCTCTGGCTCCAAAGAAAAGGACAGGAATCTTCGAAGGATC
ACCAGGATGGTGCTGGTGGTGGTGGCTGTGTTCATCGTCTGCTGGACTCCCATTCACATT
TACGTCATCATTAAAGCCTTGGTTACAATCCCAGAAACTACGTTCCAGACTGTTTCTTGG
CACTTCTGCATTGCTCTAGGTTACACAAACAGCTGCCTCAACCCAGTCCTTTATGCATTT
CTGGATGAAAACTTCAAACGATGCTTCAGAGAGTTCTGTATCCCAACCTCTTCCAACATT
GAGCAACAAAACTCCACTCGAATTCGTCAGAACACTAGAGACCACCCCTCCACGGCCAAT
ACAGTGGATAGAACTAATCATCAGCTAGAAAATCTGGAAGCAGAAACTGCTCCGTTGCCC
TAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-endorphin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein alpha-subunit binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein beta-subunit binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>morphine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neuropeptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of Wnt protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuropeptide signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>opioid receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neurogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of N-methyl-D-aspartate selective glutamate receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>